Announcements
Hogan Lovells assists EyePoint Pharmaceuticals on transformative follow-on public offering of common stock
09 February 2021
Sally Gu
AssociateWashington, D.C.
Email [email protected]hoganlovells.com
Phone +1 202 637 6856
Fax +1 202 637 5910
LanguagesEnglish
Practice groupGlobal Regulatory
Sally Gu advises clients on Food and Drug Administration (FDA) advertising and promotion issues, compliance with current good manufacturing practices (cGMP), life cycle management, and product development issues.
She routinely advises pharmaceutical companies on pre-launch and post-marketing advertising and promotion issues and has served on multiple promotional review committees. She also assists pharmaceutical clients with responses to FDA enforcement actions and related government investigations, and advises on FDA regulatory issues arising in corporate transactional matters and filings with the Securities and Exchange Commission (SEC).
While at University of Michigan Law School, Sally was a Notes Editor for the Michigan Law Review, and the President of the Michigan Health Law Organization.
In addition to assisting clients in the life sciences and health care industry, Sally is also active in the firm's Pro Bono practice.
Education and admissions
Education
J.D., University of Michigan Law School, cum laude, 2018
B.A., The University of Chicago, general honors, 2014
Bar admissions and qualifications
District of Columbia
California
Representative experience
Counsel numerous pharmaceutical companies on pre-launch and post-marketing activities, including experience on promotional review committees.
Conduct internal audits for pharmaceutical companies of promotional materials, promotional review processes and investigator initiated study programs.
Assist multiple pharmaceutical companies in responding to FDA enforcement letters, Form FDA 483 inspectional observations, and related government investigations.
